Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Recommends Genetic Testing For Plavix Response, Opens Window For Effient

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA increased the level of its Plavix warning for slow metabolizers to a black box, recommending genetic testing and advising health care professionals to consider using other anti-platelet medications or alternative dosing strategies.

You may also be interested in...

Medco Buys DNA Direct To Bolster Its Personalized Medicine Business

DNA Direct adds genetic testing guidance and decision-support capacity to Medco's burgeoning personalized medicine portfolio.

Lilly Puts On A Happy Face, But Will Investors Buy In?

It was all about the pipeline during Eli Lilly's fourth quarter earnings call, as company execs strove to convince analysts they can compensate for revenue losses from big-ticket products about to lose patent protection

FDA Updates Plavix Label, Leaves Effient With Clear Advantage

FDA's latest revision of labeling for Bristol-Myers Squibb/Sanofi Aventis' Plavix gives Lilly/Daiichi Sankyo a clear-cut advantage to use for its competing antiplatelet agent Effient: Effient can be used with the proton pump inhibitor Prilosec; Plavix cannot

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts